Inhibition of isoprenylcysteine carboxylmethyltransferase (Icmt), which catalyzes the final step in the posttranslational C-terminal processing of prenylated proteins, suppresses tumor cell growth and induces cell death. Icmt inhibition by either a small molecule inhibitor termed as cysmethynil or inhibitory RNA induces marked autophagy leading to cell death. HepG2 cells were used to investigate the function of autophagy in tumor cell death. Suppression of autophagy, either pharmacologically or through knockdown of the autophagy essential proteins, Atg5 or Atg1, inhibits not only cysmethynilinduced autophagy, but also apoptosis in HepG2 cells. The dependence of cysmethynil-induced apoptosis on autophagy was further shown using autophagy-deficient mouse embryonic fibroblast (MEF) cells. Atg5 À/À MEF cells were found to be resistant to cysmethynil-induced apoptosis, whereas wild-type MEFs showed high sensitivity to apoptosis induction. These data indicate that inhibition of Icmt can elicit cell death through two linked mechanisms, autophagy and apoptosis, and that autophagy can be an active player upstream of apoptosis in cell types capable of apoptotic cell death, such as HepG2 and MEFs. Further, treatment of mice-bearing HepG2-derived tumors with cysmethynil resulted in marked inhibition of tumor growth; analysis of tumor tissue from these mice revealed markers consistent with autophagy induction and cell growth arrest.
Introduction
Several proteins involved in oncogenesis and tumor progression undergo a three-step post-translational modification process termed as prenylation, which is initiated by attachment of an isoprenoid lipid. Prenylated proteins include most members of the Ras superfamily of GTPases as well as a number of other important regulatory proteins (Magee and Seabra, 2005; Gelb et al., 2006) . The three-step modification starts with the addition of either a farnesyl or geranylgeranyl isoprenoid to the conserved cysteine residue of the CaaX motif by protein farnesyltransferase or protein geranylgeranyltransferase type I, respectively (Zhang and Casey, 1996) . This lipidation is followed by an endoproteolytic removal of the ÀaaX residues by the Rce1 protease and subsequent carboxyl methylation of the prenylated cysteine residue by a unique methyltransferase termed as isoprenylcysteine carboxylmethyltransferase (Icmt) (Ashby, 1998; Dai et al., 1998; .
The discovery that Ras proteins are modified by farnesyltransferase, and that the modification is required for oncogenic function of these proteins, triggered the initial interest in targeting protein prenylation in cancer therapy. Although clinical trials of farnesyltransferase inhibitors are still ongoing, overall clinical response in the majority of cancers examined has been disappointing. One potential reason for the low efficacy of farnesyltransferase inhibitors often discussed is that of alternate prenylation, in which geranylgeranyltransferase type I can modify at a low level substrates of farnesyltransferase when activity of the latter is blocked (Whyte et al., 1997; Sousa et al., 2008) . In contrast, both Rce1 and Icmt are unique enzymes responsible for modification of both farnesylated and geranylgeranylated CaaX proteins, so blockade at these post-prenylation processing steps would not be subject to alternate modification bypass (Winter-Vann and Casey, 2005; Gelb et al., 2006) . Chemically, methylation of the carboxyl group neutralizes the negative charge of the group, enabling interaction with the negatively charged plasma membrane phospholipids and interactions of hydrophobic nature (Wright et al., 2009) .
The initial approach to assessing the impact of Icmt inhibition on tumorigenesis involved genetic disruption studies in mouse cells, in which it was found that eliminating Icmt activity had profound inhibitory effect on oncogenic transformation by K-Ras as well as by other oncogenes (Bergo et al., 2004; Wahlstrom et al., 2008) . Subsequent pharmacologic studies have also provided evidence that inhibition of Icmt-catalyzed methylation presents a potential approach to controlling cell prolifera-tion (Kramer et al., 2003; Anderson et al., 2005; WinterVann et al., 2005; Blum et al., 2008) . To date, the most potent pharmacologic agent targeting Icmt is a compound termed as cysmethynil, originally identified in a screen of a small molecule library containing diverse scaffolds (Baron et al., 2007) . Treatment of human colon cancer cells with cysmethynil resulted in mislocalization of Ras, impaired response to EGF treatment, and a reduction of anchorageindependent growth of these cancer cells; moreover, these effects were reversed by over-expression of Icmt (WinterVann et al., 2005) .
The impact of prenylation inhibition in tumor cell signaling has evolved from a Ras-centric view to the understanding that many other substrates of these modifications can affect tumorigenesis, depending on the specific type of cancer and its aberrancy in signaling. In this regard, our recent study suggests that induction of autophagy may be part of the antitumor efficacy of Icmt inhibitor cysmethynil (Wang et al., 2008) . Autophagy (sometimes referred to as macroautophagy) is a well-recognized cellular process involved in maintaining homeostasis by degrading macromolecules and eliminating unwanted cellular structures and organelles (Klinosky and Emr, 2000) . Autophagy is a highly conserved mechanism in eukaryotic cells that starts with the formation of double membrane-bound vacuoles, which ultimately fuse with lysosomes to degrade sequestered material. Autophagy has been closely associated with many cytoprotective processes; as examples of the functions autophagy has in normal physiological processes, its most recognized functions include limiting the deposition of aggregate-prone proteins and promoting nutrient and energy recycling (Klinosky and Emr, 2000; Kuma et al., 2004) . The misregulation of autophagy has been recognized to result in numerous pathological conditions (Huang and Klionsky, 2007) . Given its function in performing important homeostatic functions, it is not surprising that autophagy is subjected to multiple modes of regulation in response to intra-and extra-cellular stimuli (Nair and Klinosky, 2005; Botti et al., 2006) .
Autophagic cell death, also referred to as type II programmed cell death, is of clinical importance in oncology because, for many cancer types, evasion of apoptotic cell death (type I programmed cell death) contributes significantly to the tumorigenesis mechanism. Induction of autophagic cell death in these populations of cells can be a therapeutic option (Kanzawa et al., 2004; Takeuchi et al., 2005) . Furthermore, autophagy can be synergistic with apoptosis in inducing cancer cell death in radiation and chemotherapy, and frequently occurs in cells that have intact apoptotic pathways (Di et al., 2009; Gewirtz et al., 2009) , broadening the scope of clinical applicability of inducing autophagy as an anticancer strategy. Even though autophagic cell death has been classified as type II programmed cell death for some time (Schwartz et al., 1993; Bursch et al., 2000) , type I being the well-studied type of apoptotic cell death, the exact involvement of autophagy in cell death remains to be defined (Scarlatti et al., 2009) .
Controversy continues to focus on whether autophagy can be a driving mechanism of cell death in cancer chemotherapy, especially when the cells are capable of apoptosis (Levine and Kroemer, 2009 ). In non-mammalian organisms, there is convincing evidence that autophagy is a form of programmed cell death that can occur independently of apoptosis (Olie et al., 1998; Roisin-Bouffay et al., 2004) . In mammalian cells, there is also evidence suggesting that induction of autophagy can lead to cancer cell death both in cells that are capable of apoptotic cell death and in cells that are deficient in apoptotic cell death (Gorka et al., 2005; Akar et al., 2008; Lambert et al., 2008; Wang et al., 2008) . In most cases when both autophagy and apoptosis have been linked to cell death under particular conditions, no connection of dependency of one on the other has been clearly indicated. A better understanding of autophagic cell death and its connection with apoptosis would enhance not only the understanding of this important cellular regulatory mechanism, but also the identification of clinically useful new anticancer therapeutics targeting cell death processes. In this study, we report that autophagy induction resulting from Icmt inhibition can be observed in all tumor cell lines tested. The consequences of targeting Icmt in both in vitro and in vivo models of HepG2 hepatocellular cancer are detailed, and evidence is provided for the interplay between autophagy and apoptosis as an important component of the preclinical efficacy of the Icmt inhibitor observed in these models.
Results
Inhibition of Icmt by cysmethynil results in growth inhibition and cell death with apoptotic features We evaluated the in vitro efficacy of cysmethynil treatment on several human cancer cell lines, including HepG2, Huh7, and SK-Hep1 hepatocellular carcinoma cells and MDA-MB231 breast cancer cells; the earlierstudied PC3 prostate cancer cell line was assayed in the same experiments for comparison. Cysmethynil treatment of all cell lines resulted in a dose-dependent reduction in cell viability as shown in Figure 1a . Among the cells tested, hepatocellular cells Huh7 and HepG2 appear to be the most sensitive to cysmethynil treatment, whereas SK-Hep1 and Mda-MB231 cells are somewhat less responsive. Although several human cancer cells behave similarly in response to cysmethynil treatment, we chose to focus on HepG2 cells in this report as there is a reliable mouse xenograft model for drug efficacy studies in vivo with this line.
The time dependence of the response of HepG2 cells on treatment with cysmethynil was assessed. Cell growth inhibitory effect was observed early in the treatment course; flow cytometry study of HepG2 cells at 48 h of cysmethynil treatment revealed an increasing amount of G1, but few sub-G0 cells (Figure 2a) . The same study at 72 h presented with many more dead cells, depicted as the sub-G0 population (Figure 2a) . (i, ii) or with 25 mM cysmethynil (iii, iv) for 72 h, and analyzed for DNA breaks using the Tunel staining procedure (i, iii) and cell morphology by light microscopy (ii, iv). DNA fragmentations are clearly visible in the drug-treated cells (iii). (c) Caspase 3 activity analysis for apoptosis. HepG2 cells were again treated with either DMSO or cysmethynil for 24, 48, and 72 h; cell lysates were then analyzed for caspase 3 activity described in Materials and methods. (d) Analysis of select markers of cell cycle and apoptosis. HepG2 cells were treated with or without cysmethynil for the indicated times, and immunoblot analysis of the indicated protein/ phosphoprotein biomarkers was performed as described in Materials and methods. pRb795 stands for phosphorylated Rb at residue 795, and Cleaved Caspase 3 stands for cleaved caspase 3. Data shown in panels a-d are from single experiments, each of which has been performed at least twice with similar outcomes.
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Consistent with the findings of G1 cell cycle arrest and apoptosis, immunoblot analysis showed increased levels of p27 and decreased cyclin D1 and phospho-Rb, as well as the appearance of cleaved PARP and cleaved caspase3 in the cysmethynil exposed cell lysate ( Figure 2d ). These data provide clear evidence that the impact of cysmethynil treatment includes inhibition of cell cycle progression and induction of apoptosis. Of note, cells exposed to the inactive analog of cysmethynil behaved similarly as cells exposed to DMSO vehicle, suggesting target specificity of cysmethynil (data not shown).
Inhibition of Icmt induces autophagy
Microtubule-associated protein 1 light chain 3 (LC3) form II is a specific constituent of autophagosome membrane. Two forms of LC3 exist in the cells, LC3-I and LC3-II (Kabeya et al., 2000) . Although LC3-I is a cytosolic protein, LC3-II is the phosphotidylethanolamine-conjugated form generated when autophagy is induced; LC3-II then localizes to the autophagosome membrane through phosphotidylethanolamine (Kabeya et al., 2004) . Increased production of LC3-II and its translocation to autophagosome have been used as indicators for autophagy induction.
Cysmethynil treatment of HepG2 cells resulted in a dramatic elevation of the LC3-II protein (Figure 3a ) for 48 h and then subjected to immunofluorescence analysis using anti-LC3 and rhodamine-red-tagged secondary antibody (red); nuclei were stained with DAPI (blue). The table indicates the percentage of cells that contain significant LC3 aggregation, as defined by the presence of punctate LC3-positive vacuoles X1 mm, surveyed from 10 fields containing >100 cells in each treatment condition, using Olympus microscope at the magnification of 20 Â 10. The study was performed three times with similar findings. induction of autophagy, much greater than that induced in these cells by starvation or rapamycin treatment (not shown), underscores the impact of Icmt inhibition on the cellular process of autophagy.
Cysmethynil induces autophagy and apoptosis in HepG2 cells through specific inhibition of Icmt Studies were used to provide evidence that the impact of cysmethynil treatment was due to inhibition of Icmt and not a non-specific effect of the compound. First, the earlier characterized inactive structural analog of cysmethynil, J3, did not induce elevation of LC3 levels (Figure 4a MEFs, whereas there was no significant difference of caspase activity between the DMSO and cysmethyniltreated Icmt null cell (Figure 4e) . Finally, during a 48 h treatment with cysmethynil, no significant difference in viability between DMSO and cysmethynil was observed in treated Icmt null cells, in contrast to the marked reduction in viability of Icmt þ / þ cells treated with cysmethynil ( Figure 4f ). All these studies provide convincing evidence that cysmethynil-induced autophagy and apoptosis are the result of the inhibitory effect of cysmethynil on Icmt.
Excessive autophagy induced by cysmethynil leads to apoptotic cell death The observation of robust induction of both autophagy and apoptosis in HepG2 cells when Icmt was inhibited raised the question of whether these two events were linked or independent events, and whether only one or both of the two processes was responsible for the cytotoxic activity of cysmethynil. Widely used methods to study functional impact of autophagy include inhibition of the process either pharmacologically or genetically (Kuma et al., 2004; Kang et al., 2007) . A pharmacologic approach to inhibit autophagy is the usage of 3-methyladenine (3-MA) to inhibit class III PI-3 kinase, which is an upstream component of the autophagic process. When HepG2 cells were co-treated with cysmethynil and 3-MA, cell viability was markedly improved in comparison with cells treated with cysmethynil alone (Figure 5a ), suggesting a significant dependence on autophagy for cysmethynil-induced cell death. Further, 3-MA treatment resulted in not only a marked reduction of the level of LC3-II, but also a reduction of cleaved PARP in cysmethynil-treated cells by immunoblot analysis (Figure 5b ), providing further evidence that the ability of cysmethynil to elicit an apoptotic response was dependent on induction of autophagy.
The genetic approach to studying functional impact of autophagy generally involves down-regulation of a gene product essential to the process, with Atg5 as one of the most often targeted. Hence, we examined the impact of Atg5 knockdown in HepG2 cells on their response to cysmethynil. Efficient reduction of the Atg5 protein was observed on RNAi treatment (Figure 6a) . Compared with that of mock RNAi, Atg5 knockdown was accompanied by a corresponding reduction in the ability of cysmethynil to elicit elevation of the LC3-II protein, and a marked reduction of cleaved PARP. Also noteworthy is an apparent temporal delay between the induction of autophagy and apoptosis markers (Figure 6a ), suggesting that autophagy induction comes before apoptosis. Importantly, Atg5 knockdown cells exhibited significantly enhanced survival when treated with cysmethynil compared with the mock RNAitransfected cells (Figure 6b) .
We also conducted experiments with Atg1 knockdown to rule out the possibility that Atg5 knockdown directly impacting on apoptosis accounts for the outcome of reduced apoptosis (Yousefi et al., 2006) . We again observed the reduced autophagy induction (Figures 6c and d) , reduced level of apoptosis (Figure 6e) , and improved viability (Figure 6f ) of the Atg1 knockdown cells, in comparison with mock siRNA-transfected cells under the treatment of cysmethynil. Hence, the impact of both the pharmacologic and genetic suppression of autophagy on apoptosis suggests that excessive autophagy caused by cysmethynil treatment has an active function leading to apoptosis, rather than being a pro-survival mechanism or a passive accompanying phenomenon. Altogether, the evidence places autophagy induced by cysmethynil upstream of apoptosis in the cell death process in HepG2.
MEFs lacking Atg5 are resistant to cysmethynil-induced apoptosis and cell death To further address the relationship between autophagy and apoptosis in response to Icmt inhibition, we used an earlier-established MEF cell line lacking Atg5 (Kuma et al., 2004) . The advantages of choosing the MEF lines are twofold. First, the comparison of the wild-type MEF and the Atg5 À/À MEF provides a cleaner test than that using RNAi, addressing the concern for off-target effects, which may plague the siRNA knockdown. Second, the MEF lines could provide evidence that the relationship between autophagy and apoptosis under cysmethynil treatment is not limited to HepG2 cells. When wild-type MEFs were treated with 20 mM cysmethynil, autophagy and apoptosis were efficiently induced, as assessed by the induction of LC3-II and the appearance of cleaved PARP (Figure 7a) , and the accumulation of a sub-G0 population with the morphologic characteristics of apoptotic cells (Figure 7b ). In contrast, both the autophagic and apoptotic response to cysmethynil treatment were blocked in the Atg5 À/À MEFs (Figures 7a and b) . Consistent with the lack of autophagy and apoptosis, cell viability assays showed no significant decrease in viable cells in the cysmethyniltreated Atg5
À/À cells during the 48 h treatment course (Figure 7c ). The lack of apoptotic cell death in the autophagy-deficient Atg5 À/À cells treated with cysmethynil strongly supports the notion that autophagy induced by Icmt inhibition is an active component promoting apoptosis, consistent with the findings detailed in HepG2 cells. The cells were treated as described in (c); the lysates were then assayed for caspase 3 activity, which is presented relative to the level in the cells not treated with cysmethynil. (f) Viability study. Icmt þ / þ and Icmt À/À MEFs were treated with either DMSO or 20 mM cysmethynil for 24 and 48 h, and viabilities measured by the MTS assay as described in Materials and methods. Viabilities were compared with those before the treatment of each cell line, the 0 h time point.
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Cysmethynil treatment induces autophagy and cell cycle arrest, and impairs growth of HepG2-derived tumors in vivo Given the observed impact of pharmacologic suppression of Icmt on proliferation and survival of HepG2 cells, we were keen to examine the impact of cysmethynil in an in vivo model of hepatocellular carcinoma. Hence, HepG2 cells were subcutaneously implanted in the flanks of 8-10-week-old immunodeficient mice. After establishment of tumors, the tumor-bearing mice were randomized into three treatment groups of eight mice. These groups were then subjected to three treatment regimens of either vehicle (control), 0.1 or 0.2 g/kg of cysmethynil, administered every 48 h. Tumor sizes were measured and general observations were made every 48 h. As shown in Figure 8a , at both dosage levels, cysmethynil treatment had a major impact on the growth rate of the HepG2-derived tumors. The lower dosage was better tolerated by the mice, with no significant differences in body weight or appearance between the control and treated animals during the course of the study (data not shown).
In an effort to identify the molecular impact of cysmethynil treatment on cell cycle and autophagy in vivo, a parallel study was performed in which vehicle and 0.2 g/kg cysmethynil dosing groups (four mice each) were killed after six doses at day 12 and their tumors harvested for immunoblot analysis. The tumors from the cysmethynil treatment group were found to have a significant increase in the LC3-II/LC3-I ratio (Figure 8b) , indicating an elevated level of autophagy in the tumor cells of the treatment group. Similarly, the impact of cysmethynil was seen in G1 cell cycle markers; specifically, increased p27 levels and reduced cyclin D1 and phospho-Rb levels compared with the control group (Figure 8b ). These observations on cell cycle and autophagy biomarkers provide compelling evidence that the efficacy of cysmethynil in inhibiting the growth of HepG2-derived tumors is through similar mechanisms as those observed in vitro.
Discussion
Autophagy has emerged as a field of focused study because of an increasing recognition of its important functions in the regulation of cell proliferation, growth, and survival. Autophagy exists in all eukaryotic cells, having apparently evolved as a tightly regulated mechanism to cope with a nutrient-deficient environment (Kuma et al., 2004; Kang et al., 2007) . In this capacity, autophagy is mostly considered as an adaptive response in that it is pro-survival, not only by providing macromolecule building blocks and energy in nutrient poor conditions, but also by eliminating damaged proteins resulted from oxidative stress or other pathological conditions and in battling infections in mammalian cells.
Early studies on autophagy have suggested the involvement of autophagy in tumorigenesis. Genetic disruption of autophagy gene Beclin 1 results in not only reduction of autophagy, but also higher frequency of spontaneous malignancies (Yue et al., 2003) . Numerous studies suggest a correlation between autophagy disruption and the development of human cancers. For example, one copy of Beclin 1 locus was reported to be deleted in up to 75% of ovarian cancers and up to 50% deletion in breast cancers (Eccles et al., 1992; Futreal et al., 1992; Cliby et al., 1993; Saito et al., 1993) . These studies suggest a connection between subnormal quantity of autophagy and tumorigenesis. Although the question remains as to in what capacity autophagy inhibits cancer development, autophagy has been increasingly recognized as being present in, and contributing to, the process of cell death in specific contexts ( 
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The function autophagy has in cell death is especially complicated when mixed phenotypes of both autophagy and apoptosis exist, as in the case of cysmethynilinduced cell death in HepG2 cells reported here. In these cases, it is necessary to distinguish three scenarios: (i) autophagy is present with apoptosis; (ii) autophagy is a pro-survival response to the insult of the drug treatment, acting as a rescue mechanism; and (iii) autophagy has active and necessary function in the death process. In the third scenario, one can further place autophagy either upstream as a cause of apoptosis, or downstream as a consequence of apoptosis. Several studies have shown quite convincingly that autophagy can result in cell death, both in invertebrates such as Drosophila (Juhasz et al., 2003; Scott et al., 2007) and in human cells Espert et al., 2006; Wang et al., 2008) , and it is now an accepted notion that the level of autophagy in cells is closely regulated and exists in various balanced states in different cell systems, the disruption of which can cause cell death.
Through perturbing the process of autophagy through both pharmacologic and genetic means, evidence was obtained that autophagy induced in HepG2 cells by cysmethynil treatment is neither just an accompanying phenomenon nor a rescuing measure in the cell death process. The improved survival of HepG2 cells exposed to cysmethynil when autophagy was Icmt inhibition induces autophagic-dependent apoptosis M Wang et al inhibited suggests that, in this case, autophagy is an active participant in leading to cell death induced by Icmt inhibition. Further evidence in support of this conclusion came from studies with the Atg5 À/À MEF cells. The lack of Atg5 of these cells, and resultant inability to mount an autophagic response, rendered them highly insensitive to cysmethynil treatment compared with the wild-type MEFs. In addition to the absence of cysmethynil-induced autophagy in the Atg5 À/À MEFs, the apoptotic response to cysmethynil seen in the wild-type MEFs was eliminated. Taken together, these data provide convincing evidence that the presence of autophagy is necessary for the induction of apoptosis in the MEF cells exposed to cysmethynil. Hence, in both HepG2 human cancer cells and MEFs, the model of cysmethynil-induced autophagy leading to apoptosis represents the most likely pathway of cell death. The connection between autophagy and apoptosis in HepG2 and MEF cells reported here is a step forwards from our earlier study of autophagic cell death À/À MEFs were treated with vehicle (À cysm) or 20 mM cysmethynil ( þ cysm) for 48 h, whereon cells were subject to DNA content analysis (left panels) and light microscopic analysis of morphological characteristics (right panels). Arrows point to the sub-G0 populations; roughly 50% of the wildtype MEFs are found in this population after 48 h of cysmethynil treatment, whereas there is no significant increase in apoptosis in the Atg5 À/À MEF cell population. (c) Viability study. Wild-type (light gray bars) and Atg5 À/À (dark gray bars) MEFs were subject to treatment with 20 mM cysmethynil, and viabilities assessed at the indicated times. Data shown in panels a and b are from single experiments, each of which has been performed at least three times with similar outcomes. Data shown in panel c represent the mean and s.d. of triplicate determinations from a single experiment that has been performed three times with similar outcomes. ***Po0.001. in PC3 human prostate cancer cells. Although cysmethynil treatment of PC3 prostate cancer cells elicited G1 arrest and induced autophagy and cell death, no concomitant features of increasing apoptosis were found in these cells. The mechanism for the difference in apoptosis induction between HepG2 and PC3 cells is unclear, but likely involves the differences in the cellular genetic and/or epigenetic background, including p53 and PTEN, two players involved in apoptosis and survival (Crighton et al., 2006; Scarlatti et al., 2009) . In this capacity, it becomes important to identify the substrates of Icmt that serve as 'node(s)' in the complicated process of autophagy regulation in future studies.
Materials and methods

Materials
Cysmethynil was synthesized by the Duke Small Molecule Synthesis Facility through established methods and its inactive analog J3 as described (Wang et al., 2008) . 3-MA was from Sigma-Aldrich (St Louis, MO, USA). Antibodies recognizing human Atg5, cyclins D1 and B1, p27, PARP, caspase-3, Atg1, and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) were from Cell Signaling Technology (Danver, MA, USA). The anti-LC3 antibody was from Abgent (CA, USA).
Cell lines, tissue culture, and viability assay All the cancer cell lines, including HepG2 hepatocellular cell line, were obtained from American Type Culture Collection (Rockville, MD, USA); wild type and Atg5 À/À murine embryonic fibroblast were gifts from Dr Noboru Mizushima (Kuma et al., 2004) . All cells were maintained at 37 1C with 5% CO 2 in DMEM (Sigma-Aldrich) supplemented with 10% fetal bovine serum (Hyclone, Novato, CA, USA), 50 U/ml penicillin, and 50 mg/ml streptomycin (Gibco, North Andover, MA, USA). For viability determinations, cells were seeded at 15-20% confluency under standard culture condition for 24 h before treatment with specific agents or vehicle at concentrations and length of time indicated. Cysmethynil treatment of cells was performed with concentrations of 18-25 mM according to the sensitivity of different cell lines; exact conditions are noted in the respective figure legend. 3-MA was used in 0.5 mM in the media. The relative number of live cells was determined using the CellTiter 96 AQueous One Solution Cell Proliferation Assay (Promega, Madison, WI, USA). Briefly, MTS solution contains MTS compound (3-(4, 5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium), and an electron coupling reagent phenazine ethosulfate. MTS is bioreduced by live cells to a formazan product, which can be quantized colorimetrically at 490 nm absorbance.
Apoptosis measurements
Apoptosis was assessed by determination of activation of Caspase 3 and PARP activation status through immunoblot analysis, morphological observation, flow cytometry analysis, DNA fragmentation observation using the Tunel assay (Roche, NJ, USA), and caspase 3 activity assay (Clontech, CA, USA). DNA contents were analyzed by standard flow cytometry procedures. For the Tunel assay, DNA breaks were tagged by fluorescein-labeled nucleotides and quantified as described in the manufacturer's manual. Caspase 3 activity was measured by the cleavage of DEVD-AFC to produce the fluorescing AFC-substrate conjugate, as described in the manufacturer's manual.
Immunoblot and immunofluorescence analysis
For immunoblot analysis, cells were harvested, lysed, and the protein concentrations determined by Micro BCA (Pierce, Rockford, IL, USA) method. Proteins were separated by SDS-PAGE and immunoblot analysis performed using an enhanced chemiluminescence procedure (GE Healthcare, Piscataway, NJ, USA). For immunofluorescence analysis, cells were fixed with 4% paraformaldehyde and permeabilized with 0.3% Triton using a standard protocol (Spector and Smith, 1986) . Incubation with anti-LC3 (Abgent) was performed at 4 1C overnight before incubation with Rhodamine Red-X secondary antibody (Jackson Immunoresearch Laboratories, West Grove, PA, USA). Analysis was performed using an Olympus fluorescent microscope fitted with the appropriate excitation and emission filters.
RNA knockdown studies
Stealth siRNA duplex oligoribonucleotides targeting Atg5 and Atg1 (Invitrogen, Carlsbad, CA, USA) were used for their silencing, as described in Invitrogen manual. For knockdown of Icmt, we used Superarray SureSilencing shRNA plasmid with GFP marker (SA Biosciences, Frederick, MD, USA). Transfections were carried out using the optimized Lipofectamine 2000 protocol. Confirmation of knockdown was performed by reverse-transcriptase PCR for Icmt and immunoblot for Atg1 and Atg5. For RT-PCR, total RNA was extracted using Total RNA Purification System (Invitrogen). First-strand cDNAs were synthesized using SuperScript III First-Strand Synthesis System (Invitrogen), and the cDNAs from each sample was used as templates for PCR amplification. PCR was performed with optimized condition for each cDNA before agarose gel analysis. GAPDH was the internal control.
Cysmethynil treatment of xenograft-harboring mice HepG2 cells (5 Â 10 6 ) were mixed with Matrigel (BD Biosciences, Bedford, MA, USA) to achieve 40% Matrigel in the final solution. The cell preparation was then injected subcutaneously into the flanks of 8-10-week-old severe combined immunodeficient mice. Cysmethynil was prepared and dosed at 0.1 and 0.2 g/kg in two groups, together with the control group, at 48 h intervals as described (Wang et al., 2008) . Subcutaneous tumors were measured with the standard clipper ruler method. Final tumor weight at the end of the study was documented after animal killing and dissection of tumor tissue. In a separate study, eight tumor-bearing mice were randomized to two separate groups of vehicle and treatment (0.2 g/kg) groups. The mice were killed on day 12 and tumor tissue collected for immunoblot analysis. During the course of the treatment, animals were monitored daily; general health and weight were examined and documented every 48 h. All mice were maintained according to the Guide for the Care and Use of Laboratory Animals.
